Abramson Cancer Center at Penn Medicine
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
Urothelial Carcinoma Bladder
Bladder Cancer
Concurrent Immunotherapy and Radiation Therapy
PHASE1
Patients in this study will receive the standard of care procedures and follow-up for immunotherapy and radiation therapy. The part of this study that is research is receiving both of these treatments at the same time. Safety will be based on acute toxicity.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 10 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Phase I Safety Trial of Concurrent Adjuvant Immunotherapy and Radiation Therapy for the Treatment of Urothelial Bladder Cancer |
Actual Study Start Date : | 2025-04-29 |
Estimated Primary Completion Date : | 2027-04 |
Estimated Study Completion Date : | 2027-04 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104